At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ESMO President-Elect Professor Giuseppe Curigliano of the European Institute of Oncology (IEO), Milan, Italy, presented findings from the patient-reported outcomes (PRO) analysis of the Phase III EMBER-3 trial. The data revealed changes in overall health status, quality of life, and physical function scores in patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer treated with either imlunestrant alone or in combination with abemaciclib. Oncology Frontier conducted an exclusive interview with Professor Curigliano at the conference to discuss the clinical applicability of imlunestrant monotherapy and its combination with abemaciclib, as well as their impact on patient quality of life—offering new perspectives for clinical practice.

Antibody–drug conjugates (ADCs) targeting HER2 have already transformed the treatment landscape in advanced breast cancer and are now making their way into early-stage settings. At the 2025 ASCO Annual Meeting, Professor Junjie Li from Fudan University Shanghai Cancer Center presented results from a phase II clinical study investigating a novel HER2 bispecific ADC, TQB2102, in the neoadjuvant treatment of HER2-positive early breast cancer. The study delivered striking pathological complete response (pCR) results, suggesting strong potential for clinical impact. Below is an on-site interview with Professor Li, summarizing the key findings.

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 30 to June 3. At the conference, Professor Ting Li of Fudan University Shanghai Cancer Center delivered a Rapid Oral Abstract presentation on behalf of her team, showcasing a phase II clinical study (Abstract #1018) titled "A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases." Following her presentation, Oncology Frontier conducted an exclusive interview with Professor Li, where she shared insights into the rationale behind the study design, the benefits of the triplet therapy, and the specific patient groups most likely to benefit.

A dynamic understanding of the tumor microenvironment (TME) is essential for uncovering the mechanisms behind treatment response and disease progression. At the 2025 ASCO Annual Meeting, Professor Jieqiong Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, presented an innovative translational study (Abstract #1022) exploring the efficacy and safety of a novel combination therapy in patients with HER2-positive metastatic breast cancer who had failed second-line or later treatments. The team employed single-cell sequencing to analyze TME changes before and after treatment with KN046, a bispecific anti-CTLA-4/PD-L1 antibody, and KN026, a bispecific anti-HER2 antibody. The results revealed distinct immunological  differences between responders and non-responders and identified the baseline macrophage-to-lymphatic endothelial cell (Mϕ/LEC) ratio as a predictive biomarker of treatment response. This study offers new insights into individualized care strategies for breast cancer.